These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 30099250)

  • 21. Compensatory effects in the PI3K/PTEN/AKT signaling network following receptor tyrosine kinase inhibition.
    Goltsov A; Faratian D; Langdon SP; Bown J; Goryanin I; Harrison DJ
    Cell Signal; 2011 Feb; 23(2):407-16. PubMed ID: 20951800
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies.
    Stommel JM; Kimmelman AC; Ying H; Nabioullin R; Ponugoti AH; Wiedemeyer R; Stegh AH; Bradner JE; Ligon KL; Brennan C; Chin L; DePinho RA
    Science; 2007 Oct; 318(5848):287-90. PubMed ID: 17872411
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Checks and balances: interplay of RTKs and PTPs in cancer progression.
    Sastry SK; Elferink LA
    Biochem Pharmacol; 2011 Sep; 82(5):435-40. PubMed ID: 21704606
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Acquired Resistance Is Oncogene and Drug Agnostic.
    Doebele RC
    Cancer Cell; 2019 Oct; 36(4):347-349. PubMed ID: 31614114
    [TBL] [Abstract][Full Text] [Related]  

  • 25. RTKs in pathobiology of head and neck cancers.
    Nadhan R; Srinivas P; Pillai MR
    Adv Cancer Res; 2020; 147():319-373. PubMed ID: 32593405
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Serotonin derivatives as a new class of non-ATP-competitive receptor tyrosine kinase inhibitors.
    Büttner A; Cottin T; Xu J; Tzagkaroulaki L; Giannis A
    Bioorg Med Chem; 2010 May; 18(10):3387-402. PubMed ID: 20456957
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Artificial signal transduction therapy: a futuristic approach to disease treatment.
    Peri-Naor R; Motiei L; Margulies D
    Future Med Chem; 2015; 7(16):2091-3. PubMed ID: 26510968
    [No Abstract]   [Full Text] [Related]  

  • 28. Receptor tyrosine kinases: from biology to pathology.
    Choura M; Rebaï A
    J Recept Signal Transduct Res; 2011 Dec; 31(6):387-94. PubMed ID: 22040163
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Oligonucleotide aptamers against tyrosine kinase receptors: Prospect for anticancer applications.
    Camorani S; Crescenzi E; Fedele M; Cerchia L
    Biochim Biophys Acta Rev Cancer; 2018 Apr; 1869(2):263-277. PubMed ID: 29574128
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genetic events that limit the efficacy of MEK and RTK inhibitor therapies in a mouse model of KRAS-driven pancreatic cancer.
    Pettazzoni P; Viale A; Shah P; Carugo A; Ying H; Wang H; Genovese G; Seth S; Minelli R; Green T; Huang-Hobbs E; Corti D; Sanchez N; Nezi L; Marchesini M; Kapoor A; Yao W; Francesco ME; Petrocchi A; Deem AK; Scott K; Colla S; Mills GB; Fleming JB; Heffernan TP; Jones P; Toniatti C; DePinho RA; Draetta GF
    Cancer Res; 2015 Mar; 75(6):1091-101. PubMed ID: 25736685
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting mTOR signaling in lung cancer.
    Marinov M; Fischer B; Arcaro A
    Crit Rev Oncol Hematol; 2007 Aug; 63(2):172-82. PubMed ID: 17540577
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Roles for deregulated receptor tyrosine kinases and their downstream signaling molecules in hematologic malignancies.
    Matsumura I; Mizuki M; Kanakura Y
    Cancer Sci; 2008 Mar; 99(3):479-85. PubMed ID: 18177485
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The anti-angiogenic and anti-tumor activity of synthetic phenylpropenone derivatives is mediated through the inhibition of receptor tyrosine kinases.
    Lee JS; Kang Y; Kim JT; Thapa D; Lee ES; Kim JA
    Eur J Pharmacol; 2012 Feb; 677(1-3):22-30. PubMed ID: 22200628
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Receptor tyrosine kinase inhibitors in cancer.
    Ebrahimi N; Fardi E; Ghaderi H; Palizdar S; Khorram R; Vafadar R; Ghanaatian M; Rezaei-Tazangi F; Baziyar P; Ahmadi A; Hamblin MR; Aref AR
    Cell Mol Life Sci; 2023 Mar; 80(4):104. PubMed ID: 36947256
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Design and synthesis of constrained analogs of LCRF-0004 as potent RON tyrosine kinase inhibitors.
    Raeppel SL; Therrien E; Raeppel F
    Bioorg Med Chem Lett; 2015 Sep; 25(17):3706-10. PubMed ID: 26112445
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Crosstalk coregulation mechanisms of G protein-coupled receptors and receptor tyrosine kinases.
    Natarajan K; Berk BC
    Methods Mol Biol; 2006; 332():51-77. PubMed ID: 16878685
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Application of computational approaches to study signalling networks of nuclear and Tyrosine kinase receptors.
    Choura M; Rebaï A
    Biol Direct; 2010 Oct; 5():58. PubMed ID: 20937105
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Resistance mediated by alternative receptor tyrosine kinases in FGFR1-amplified lung cancer.
    Adachi Y; Watanabe K; Kita K; Kitai H; Kotani H; Sato Y; Inase N; Yano S; Ebi H
    Carcinogenesis; 2017 Oct; 38(11):1063-1072. PubMed ID: 28968756
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Oncogenic fusion tyrosine kinases as molecular targets for anti-cancer therapy.
    Gunby RH; Sala E; Tartari CJ; Puttini M; Gambacorti-Passerini C; Mologni L
    Anticancer Agents Med Chem; 2007 Nov; 7(6):594-611. PubMed ID: 18045055
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Receptor tyrosine kinases and their activation in melanoma.
    Easty DJ; Gray SG; O'Byrne KJ; O'Donnell D; Bennett DC
    Pigment Cell Melanoma Res; 2011 Jun; 24(3):446-61. PubMed ID: 21320293
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.